scholarly journals Added Value of Tomoelastography for Characterization of Pancreatic Neuroendocrine Tumor Aggressiveness Based on Stiffness

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5185
Author(s):  
Emin Gültekin ◽  
Christoph Wetz ◽  
Jürgen Braun ◽  
Dominik Geisel ◽  
Christian Furth ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Diagnostic Performance ◽  
Quantitative Imaging ◽  
Pancreatic Neuroendocrine Tumor ◽  
Pancreatic Tissue ◽  
Added Value ◽  
Tumor Aggressiveness ◽  
Shear Wave Speed ◽  
Imaging Markers

Purpose: To evaluate the diagnostic performance of tomoelastography in differentiating pancreatic neuroendocrine tumors (PNETs) from healthy pancreatic tissue and to assess the prediction of tumor aggressiveness by correlating PNET stiffness with PET derived asphericity. Methods: 13 patients with PNET were prospectively compared to 13 age-/sex-matched heathy volunteers (CTR). Multifrequency MR elastography was combined with tomoelastography-postprocessing to provide high-resolution maps of shear wave speed (SWS in m/s). SWS of pancreatic neuroendocrine tumor (PNET-T) were compared with nontumorous pancreatic tissue in patients with PNET (PNET-NT) and heathy pancreatic tissue (CTR). The diagnostic performance of tomoelastography was evaluated by ROC-AUC analysis. PNET-SWS correlations were calculated with Pearson’s r. Results: SWS was higher in PNET-T (2.02 ± 0.61 m/s) compared to PNET-NT (1.31 ± 0.18 m/s, p < 0.01) and CTR (1.26 ± 0.09 m/s, p < 0.01). An SWS-cutoff of 1.46 m/s distinguished PNET-T from PNET-NT (AUC = 0.89; sensitivity = 0.85; specificity = 0.92) and a cutoff of 1.49 m/s differentiated pancreatic tissue of CTR from PNET-T (AUC = 0.96; sensitivity = 0.92; specificity = 1.00). The SWS of PNET-T was positively correlated with PET derived asphericity (r = 0.81; p = 0.01). Conclusions: Tomoelastography provides quantitative imaging markers for the detection of PNET and the prediction of greater tumor aggressiveness by increased stiffness.

scholarly journals Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor

2019 ◽  
Vol 5 (3) ◽  
pp. a003814 ◽  
Author(s):  
Laura M. Williamson ◽  
Michael Steel ◽  
Jasleen K. Grewal ◽  
My Lihn Thibodeau ◽  
Eric Y. Zhao ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Genomic Characterization ◽  
Well Differentiated ◽  
Grade 3

scholarly journals Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components

2021 ◽  
Vol 11 ◽  
Author(s):  
Jean-Luc Raoul ◽  
Marie-Françoise Heymann ◽  
Frédéric Dumont ◽  
Alain Morel ◽  
Hélène Senellart ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Large Cell ◽  
Genomic Signatures ◽  
Pancreatic Net ◽  
Genomic Characterization ◽  
Poorly Differentiated ◽  
Grade 3

Temporal and spatial tumor heterogeneity can be observed in pancreatic neuroendocrine tumor. We report the case of a young woman with long term stabilization of a G2 metastatic pancreatic NET that, after pregnancy, suddenly progressed into one single liver metastasis corresponding to a transformation into G3 large-cell neuroendocrine cancer. The patient underwent liver resection (the progressive and one dormant metastasis). With a 45 months follow-up the patient is without evolutive disease. Exome sequencing of the two metastases revealed completely different genomic signatures and gene alterations: the dormant metastasis was MSS without any gene alteration; the poorly differentiated tumor was MSI, with gain of many mutations including MEN1, BCL2, MLH1 and TP53 corresponding to a mutational signature 11. Could temozolomide play a role in this transformation?

Characterization of signaling pathways and molecular mechanisms underlying kisspeptin response in pancreatic neuroendocrine tumor (panNETs) cells

2021 ◽  
Author(s):  
C Fuentes-Fayos Antonio ◽  
Alors-Pérez Emilia ◽  
Pedraza Arévalo Sergio ◽  
D. Herrera-Martínez Aura ◽  
Angel Días-Pérez Jose ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Signaling Pathways ◽  
Molecular Mechanisms ◽  
Pancreatic Neuroendocrine Tumor

scholarly journals α-Internexin: A Novel Biomarker for Pancreatic Neuroendocrine Tumor Aggressiveness

2014 ◽  
Vol 99 (5) ◽  
pp. E786-E795 ◽  
Author(s):  
Bei Liu ◽  
Laura H. Tang ◽  
Zhaojun Liu ◽  
Mei Mei ◽  
Run Yu ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Aggressiveness

Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos)

2018 ◽  
Vol 87 (6) ◽  
pp. 1481-1488 ◽  
Author(s):  
Maxime Palazzo ◽  
Bertrand Napoléon ◽  
Rodica Gincul ◽  
Mathieu Pioche ◽  
Bertrand Pujol ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Aggressiveness

The V369M Gcgr knock-in mice are a precision medicine model of mild Mahvash disease

2020 ◽  
Vol 477 (15) ◽  
pp. 2873-2874
Author(s):  
Run Yu
Keyword(s):  
Neuroendocrine Tumor ◽  
Precision Medicine ◽  
Metabolic Profile ◽  
Pancreatic Neuroendocrine Tumor ◽  
Mutant Mice ◽  
Glucagon Receptor ◽  
Biochemical Journal ◽  
Pancreas Morphology ◽  
Inactivating Mutations

The detailed metabolic characterization of the glucagon receptor (Gcgr)V369M+/+ mutant mice described in Lin et al. in the Biochemical Journal is of interest and resulting in the expected metabolic profile. We would like to point out that these mice might also be extremely useful as a precision medicine model of mild Mahvash disease, a rare hereditary pancreatic neuroendocrine tumor syndrome characterized by inactivating mutations in the glucagon receptor. Further characterization of pancreas morphology and histology in the GcgrV369M+/+ mice at more advanced ages will be critically important to understand mild Mahvash disease in humans.

scholarly journals 18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Marcello Moro Queiroz ◽  
Carlos Diego Holanda Lopes ◽  
Alessandra Corte Real Salgues ◽  
Felipe de Galiza Barbosa ◽  
Emerson Shigueaki Abe ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Pancreatic Neuroendocrine Tumor ◽  
Standard Uptake Value ◽  
Histopathological Analysis ◽  
Low Grade ◽  
High Grade ◽  
Ki 67

Abstract Background Pancreatic neuroendocrine tumor (PNET) is a subgroup of neuroendocrine tumor (NET) that has unique biology and natural history. The histological classification has a major role in the management of this pathology, but in recent years Gallium 68 dotatate (68Ga-DOTA) scanning is at the center of a discussion about how these imaging technologies can modify clinical management of neuroendocrine tumors and how their results are correlated to Ki67 index. Method We hereby describe a case of a patient that investigated an unspecific stable pancreatic nodule suspected of high-grade NET after evaluation with 68Ga-DOTATOC positron emission tomography—computed tomography (PETCT) and 18F-Fluorodeoxyglucose (18F-FDG) PETCT. Results The images corroborate the hypothesis of high-grade NET based on the standard uptake value (SUV) described in both image exams (16.4 in 18FDG PETCT and 9.2 in 68Ga-DOTATOC PETCT). After surgery, the histopathological analyses revealed a localized grade 2 well-differentiated NET, Ki-67 of 4.7, glucose transport proteins 1 (GLUT1) negative by immunohistochemistry, evidencing a rare case of mismatch between the functional image and the in vivo characterization of the neoplasm. Conclusion Functional imaging of neuroendocrine tumors with different modalities of PETCT is a well-described strategy for evaluating PNET and can dictate conducts in some cases. However, histopathological analysis is crucial to confirm the grade and prognosis related to this disease.

scholarly journals 18F-FDG PETCT and 68Ga-DOTA PETCT Mismatch With in Vivo Histopathological Characterization of Low Grade Neuroendocrine Pancreatic Tumor

2021 ◽  
Author(s):  
Marcello Moro Queiroz ◽  
Carlos Diego Holanda Lopes ◽  
Alessandra Corte Real Salgues ◽  
Felipe de Galiza Barbosa ◽  
Emerson Shigueaki Abe ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Pancreatic Neuroendocrine Tumor ◽  
Standard Uptake Value ◽  
Histopathological Analysis ◽  
Low Grade ◽  
High Grade ◽  
Ki 67

Abstract BackgroundPancreatic neuroendocrine tumor (PNET) is a subgroup of neuroendocrine tumor (NET) that has unique biology and natural history. The histological classification has a major role in the management of this pathology, but in recent years Gallium 68 dotatate (68Ga-DOTA) scanning is at the center of a discussion about how these imaging technologies can modify clinical management of neuroendocrine tumors and how their results are correlated to Ki67 index.MethodWe hereby describe a case of a patient that investigated an unspecific stable pancreatic nodule suspected of high-grade NET after evaluation with 68Ga-DOTATOC positron emission tomography - computed tomography (PETCT) and 18F-Fluorodeoxyglucose (18F-FDG) PETCT. ResultsThe images corroborate the hypothesis of high-grade NET based on the standard uptake value (SUV) described in both image exams (16.4 in 18FDG PETCT and 9.2 in 68Ga-DOTATOC PETCT). After surgery, the histopathological analyses revealed a localized grade 2 well differentiated NET, Ki-67 of 4.7, evidencing a rare case of mismatch between the functional image and the in vivo characterization of the neoplasm.ConclusionFunctional imaging of neuroendocrine tumors with different modalities of PETCT is a well-described strategy for evaluating PNET and can dictate conducts in some cases. However, histopathological analysis is crucial to confirm the grade and prognosis related to this disease. Besides the rarity of this case, our patient presented a mismatch between imaging and histopathological analysis, with the former one allowing active surveillance based on a low-grade neuroendocrine tumor.

Sign in / Sign up

Export Citation Format

Share Document